schliessen

Filtern

 

Bibliotheken

Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China

Thalidomide is effective for treating severe cutaneous lupus patients. The aim of this study was to observe the optimum effective and maintenance doses of thalidomide to maximize clinical benefit and minimize side effects for patients with cutaneous lupus in China. Sixty-nine patients with lupus ras... Full description

Journal Title: Clinical rheumatology 2016-04-21, Vol.35 (6), p.1521-1527
Main Author: Wang, Dandan
Other Authors: Chen, Haifeng , Wang, Shiying , Zou, Yaohong , Li, Jing , Pan, Jieping , Wang, Xiangdang , Ren, Tianli , Zhang, Yu , Chen, Zhiwei , Feng, Xuebing , Sun, Lingyun
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: London: Springer London
ID: ISSN: 0770-3198
Link: https://www.ncbi.nlm.nih.gov/pubmed/27097914
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1789760743
title: Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China
format: Article
creator:
  • Wang, Dandan
  • Chen, Haifeng
  • Wang, Shiying
  • Zou, Yaohong
  • Li, Jing
  • Pan, Jieping
  • Wang, Xiangdang
  • Ren, Tianli
  • Zhang, Yu
  • Chen, Zhiwei
  • Feng, Xuebing
  • Sun, Lingyun
subjects:
  • Adolescent
  • Adult
  • Blood Sedimentation
  • China
  • Constipation - etiology
  • Dose-Response Relationship, Drug
  • Exanthema - drug therapy
  • Female
  • Hospitals
  • Humans
  • Immunosuppressive Agents - administration & dosage
  • Immunosuppressive Agents - adverse effects
  • Lupus
  • Lupus Erythematosus, Cutaneous - drug therapy
  • Lupus Erythematosus, Systemic - complications
  • Male
  • Medicine
  • Medicine & Public Health
  • Middle Aged
  • Original Article
  • Remission Induction
  • Rheumatology
  • Skin
  • Sleep Stages - drug effects
  • Systemic lupus erythematosus
  • Thalidomide
  • Thalidomide - administration & dosage
  • Thalidomide - adverse effects
  • Tumor Necrosis Factor-alpha - blood
  • Young Adult
ispartof: Clinical rheumatology, 2016-04-21, Vol.35 (6), p.1521-1527
description: Thalidomide is effective for treating severe cutaneous lupus patients. The aim of this study was to observe the optimum effective and maintenance doses of thalidomide to maximize clinical benefit and minimize side effects for patients with cutaneous lupus in China. Sixty-nine patients with lupus rash from eight hospitals in China were enrolled and treated with different doses of thalidomide. We started the dose of thalidomide at 25 mg daily and gradually increased administration dose once a week until erythema was markedly improved. The effective and maintenance doses were documented. The size of skin lesions was noted once a week. Systemic lupus erythematosus disease activity index (SLEDAI) score, levels of erythrocyte sedimentation rate (ESR), and serum TNF-α were measured before and after treatment. The remission rates were evaluated weekly until 8 weeks. Sixty-eight percent of patients showed an effective dose of 50 mg daily; another 13, 10, and 9 % of patients had an effective dose of 100, 75, and 25 mg daily, respectively. The maintenance dose was 50 mg daily for 71 % of the patients, and 100, 75, and 25 mg daily for 9, 14, and 6 % of the patients. SLEDAI score and serum ESR levels significantly decreased 4 weeks after thalidomide treatment. At the end of the fourth week, the rates of complete remission, partial remission, and no response were 56 % ( n  = 39), 41 % ( n  = 28), and 3 % ( n  = 2). At the eighth week, the rate of total remission rose up to 100 %. The most common side effects were drowsiness and constipation. No peripheral neuropathy was observed in these patients. Thalidomide at a dose of 50 mg daily may offer a better benefit to risk ratio in the treatment of Chinese cutaneous lupus patients.
language: eng
source:
identifier: ISSN: 0770-3198
fulltext: no_fulltext
issn:
  • 0770-3198
  • 1434-9949
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.4196367
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_1789760743
sourceformatXML
sourcesystemPC
galeidA452506897
sourcerecordidA452506897
originalsourceidFETCH-LOGICAL-c2973-30718cb940fc7481edafced48d90f5ddeba3576b8ee8aef1059e0d65352c989b0
addsrcrecordideNp1kU9v1DAQxS0EotvCB-CCLHHhkjJOnNjmVq2gIFXiUs6WY0-6rpJ4sZ3Dfvs6pPwVyNJY8vzm6Y0fIa8YXDIA8S6V2okKWFc1dVvKE7JjvOGVUlw9JTsQAqqGKXlGzlO6B4BaKvacnNUClFCM78jh9mBG78LkHdIc0eQJ50z9TO2SzYxhSXTE5MOcaBhoOqWMk7d0XI6lg_GUDziZHNKS3lNDp2XM3hYFjDTlxZ1Wpf3Bz-YFeTaYMeHLx_uCfP344Xb_qbr5cv15f3VT2VqJpmpAMGl7xWGwgkuGzgwWHZdOwdA6h71pWtH1ElEaHBi0CsF1bdPWVknVwwV5u-keY_i2YMp68sniOG7LaCakEh0I3hT0zV_ofVjiXNx9p1ijWs5-UXdmRO3nIeRo7Cqqr3hbt9AVwUJd_oMqx63fFWYcfHn_Y4BtAzaGlCIO-hj9ZOJJM9BrunpLV5d09ZquXg2_fjS89BO6nxM_4ixAvQGptOY7jL9t9F_VB4atr3M
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1789139541
display
typearticle
titleThalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China
creatorWang, Dandan ; Chen, Haifeng ; Wang, Shiying ; Zou, Yaohong ; Li, Jing ; Pan, Jieping ; Wang, Xiangdang ; Ren, Tianli ; Zhang, Yu ; Chen, Zhiwei ; Feng, Xuebing ; Sun, Lingyun
creatorcontribWang, Dandan ; Chen, Haifeng ; Wang, Shiying ; Zou, Yaohong ; Li, Jing ; Pan, Jieping ; Wang, Xiangdang ; Ren, Tianli ; Zhang, Yu ; Chen, Zhiwei ; Feng, Xuebing ; Sun, Lingyun
descriptionThalidomide is effective for treating severe cutaneous lupus patients. The aim of this study was to observe the optimum effective and maintenance doses of thalidomide to maximize clinical benefit and minimize side effects for patients with cutaneous lupus in China. Sixty-nine patients with lupus rash from eight hospitals in China were enrolled and treated with different doses of thalidomide. We started the dose of thalidomide at 25 mg daily and gradually increased administration dose once a week until erythema was markedly improved. The effective and maintenance doses were documented. The size of skin lesions was noted once a week. Systemic lupus erythematosus disease activity index (SLEDAI) score, levels of erythrocyte sedimentation rate (ESR), and serum TNF-α were measured before and after treatment. The remission rates were evaluated weekly until 8 weeks. Sixty-eight percent of patients showed an effective dose of 50 mg daily; another 13, 10, and 9 % of patients had an effective dose of 100, 75, and 25 mg daily, respectively. The maintenance dose was 50 mg daily for 71 % of the patients, and 100, 75, and 25 mg daily for 9, 14, and 6 % of the patients. SLEDAI score and serum ESR levels significantly decreased 4 weeks after thalidomide treatment. At the end of the fourth week, the rates of complete remission, partial remission, and no response were 56 % ( n  = 39), 41 % ( n  = 28), and 3 % ( n  = 2). At the eighth week, the rate of total remission rose up to 100 %. The most common side effects were drowsiness and constipation. No peripheral neuropathy was observed in these patients. Thalidomide at a dose of 50 mg daily may offer a better benefit to risk ratio in the treatment of Chinese cutaneous lupus patients.
identifier
0ISSN: 0770-3198
1EISSN: 1434-9949
2DOI: 10.1007/s10067-016-3256-3
3PMID: 27097914
languageeng
publisherLondon: Springer London
subjectAdolescent ; Adult ; Blood Sedimentation ; China ; Constipation - etiology ; Dose-Response Relationship, Drug ; Exanthema - drug therapy ; Female ; Hospitals ; Humans ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - adverse effects ; Lupus ; Lupus Erythematosus, Cutaneous - drug therapy ; Lupus Erythematosus, Systemic - complications ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Original Article ; Remission Induction ; Rheumatology ; Skin ; Sleep Stages - drug effects ; Systemic lupus erythematosus ; Thalidomide ; Thalidomide - administration & dosage ; Thalidomide - adverse effects ; Tumor Necrosis Factor-alpha - blood ; Young Adult
ispartofClinical rheumatology, 2016-04-21, Vol.35 (6), p.1521-1527
rights
0International League of Associations for Rheumatology (ILAR) 2016
1COPYRIGHT 2016 Springer
lds50peer_reviewed
citesFETCH-LOGICAL-c2973-30718cb940fc7481edafced48d90f5ddeba3576b8ee8aef1059e0d65352c989b0
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27097914$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Wang, Dandan
1Chen, Haifeng
2Wang, Shiying
3Zou, Yaohong
4Li, Jing
5Pan, Jieping
6Wang, Xiangdang
7Ren, Tianli
8Zhang, Yu
9Chen, Zhiwei
10Feng, Xuebing
11Sun, Lingyun
title
0Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China
1Clinical rheumatology
addtitle
0Clin Rheumatol
1Clin Rheumatol
descriptionThalidomide is effective for treating severe cutaneous lupus patients. The aim of this study was to observe the optimum effective and maintenance doses of thalidomide to maximize clinical benefit and minimize side effects for patients with cutaneous lupus in China. Sixty-nine patients with lupus rash from eight hospitals in China were enrolled and treated with different doses of thalidomide. We started the dose of thalidomide at 25 mg daily and gradually increased administration dose once a week until erythema was markedly improved. The effective and maintenance doses were documented. The size of skin lesions was noted once a week. Systemic lupus erythematosus disease activity index (SLEDAI) score, levels of erythrocyte sedimentation rate (ESR), and serum TNF-α were measured before and after treatment. The remission rates were evaluated weekly until 8 weeks. Sixty-eight percent of patients showed an effective dose of 50 mg daily; another 13, 10, and 9 % of patients had an effective dose of 100, 75, and 25 mg daily, respectively. The maintenance dose was 50 mg daily for 71 % of the patients, and 100, 75, and 25 mg daily for 9, 14, and 6 % of the patients. SLEDAI score and serum ESR levels significantly decreased 4 weeks after thalidomide treatment. At the end of the fourth week, the rates of complete remission, partial remission, and no response were 56 % ( n  = 39), 41 % ( n  = 28), and 3 % ( n  = 2). At the eighth week, the rate of total remission rose up to 100 %. The most common side effects were drowsiness and constipation. No peripheral neuropathy was observed in these patients. Thalidomide at a dose of 50 mg daily may offer a better benefit to risk ratio in the treatment of Chinese cutaneous lupus patients.
subject
0Adolescent
1Adult
2Blood Sedimentation
3China
4Constipation - etiology
5Dose-Response Relationship, Drug
6Exanthema - drug therapy
7Female
8Hospitals
9Humans
10Immunosuppressive Agents - administration & dosage
11Immunosuppressive Agents - adverse effects
12Lupus
13Lupus Erythematosus, Cutaneous - drug therapy
14Lupus Erythematosus, Systemic - complications
15Male
16Medicine
17Medicine & Public Health
18Middle Aged
19Original Article
20Remission Induction
21Rheumatology
22Skin
23Sleep Stages - drug effects
24Systemic lupus erythematosus
25Thalidomide
26Thalidomide - administration & dosage
27Thalidomide - adverse effects
28Tumor Necrosis Factor-alpha - blood
29Young Adult
issn
00770-3198
11434-9949
fulltextfalse
rsrctypearticle
creationdate2016
recordtypearticle
recordideNp1kU9v1DAQxS0EotvCB-CCLHHhkjJOnNjmVq2gIFXiUs6WY0-6rpJ4sZ3Dfvs6pPwVyNJY8vzm6Y0fIa8YXDIA8S6V2okKWFc1dVvKE7JjvOGVUlw9JTsQAqqGKXlGzlO6B4BaKvacnNUClFCM78jh9mBG78LkHdIc0eQJ50z9TO2SzYxhSXTE5MOcaBhoOqWMk7d0XI6lg_GUDziZHNKS3lNDp2XM3hYFjDTlxZ1Wpf3Bz-YFeTaYMeHLx_uCfP344Xb_qbr5cv15f3VT2VqJpmpAMGl7xWGwgkuGzgwWHZdOwdA6h71pWtH1ElEaHBi0CsF1bdPWVknVwwV5u-keY_i2YMp68sniOG7LaCakEh0I3hT0zV_ofVjiXNx9p1ijWs5-UXdmRO3nIeRo7Cqqr3hbt9AVwUJd_oMqx63fFWYcfHn_Y4BtAzaGlCIO-hj9ZOJJM9BrunpLV5d09ZquXg2_fjS89BO6nxM_4ixAvQGptOY7jL9t9F_VB4atr3M
startdate20160421
enddate20160421
creator
0Wang, Dandan
1Chen, Haifeng
2Wang, Shiying
3Zou, Yaohong
4Li, Jing
5Pan, Jieping
6Wang, Xiangdang
7Ren, Tianli
8Zhang, Yu
9Chen, Zhiwei
10Feng, Xuebing
11Sun, Lingyun
general
0Springer London
1Springer
2Springer Nature B.V
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BSHEE
93V.
107T5
117X7
127XB
1388E
148AO
158FI
168FJ
178FK
18ABUWG
19BENPR
20FYUFA
21GHDGH
22H94
23K9.
24M0S
25M1P
26PQEST
27PQQKQ
28PQUKI
29PRINS
307X8
sort
creationdate20160421
titleThalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China
authorWang, Dandan ; Chen, Haifeng ; Wang, Shiying ; Zou, Yaohong ; Li, Jing ; Pan, Jieping ; Wang, Xiangdang ; Ren, Tianli ; Zhang, Yu ; Chen, Zhiwei ; Feng, Xuebing ; Sun, Lingyun
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c2973-30718cb940fc7481edafced48d90f5ddeba3576b8ee8aef1059e0d65352c989b0
rsrctypearticles
prefilterarticles
languageeng
creationdate2016
topic
0Adolescent
1Adult
2Blood Sedimentation
3China
4Constipation - etiology
5Dose-Response Relationship, Drug
6Exanthema - drug therapy
7Female
8Hospitals
9Humans
10Immunosuppressive Agents - administration & dosage
11Immunosuppressive Agents - adverse effects
12Lupus
13Lupus Erythematosus, Cutaneous - drug therapy
14Lupus Erythematosus, Systemic - complications
15Male
16Medicine
17Medicine & Public Health
18Middle Aged
19Original Article
20Remission Induction
21Rheumatology
22Skin
23Sleep Stages - drug effects
24Systemic lupus erythematosus
25Thalidomide
26Thalidomide - administration & dosage
27Thalidomide - adverse effects
28Tumor Necrosis Factor-alpha - blood
29Young Adult
toplevelpeer_reviewed
creatorcontrib
0Wang, Dandan
1Chen, Haifeng
2Wang, Shiying
3Zou, Yaohong
4Li, Jing
5Pan, Jieping
6Wang, Xiangdang
7Ren, Tianli
8Zhang, Yu
9Chen, Zhiwei
10Feng, Xuebing
11Sun, Lingyun
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Academic OneFile (A&I only)
8ProQuest Central (Corporate)
9Immunology Abstracts
10Health & Medical Collection
11ProQuest Central (purchase pre-March 2016)
12Medical Database (Alumni Edition)
13ProQuest Pharma Collection
14Hospital Premium Collection
15Hospital Premium Collection (Alumni Edition)
16ProQuest Central (Alumni) (purchase pre-March 2016)
17ProQuest Central (Alumni Edition)
18ProQuest Central
19Health Research Premium Collection
20Health Research Premium Collection (Alumni)
21AIDS and Cancer Research Abstracts
22ProQuest Health & Medical Complete (Alumni)
23Health & Medical Collection (Alumni Edition)
24Medical Database
25ProQuest One Academic Eastern Edition
26ProQuest One Academic
27ProQuest One Academic UKI Edition
28ProQuest Central China
29MEDLINE - Academic
jtitleClinical rheumatology
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Wang, Dandan
1Chen, Haifeng
2Wang, Shiying
3Zou, Yaohong
4Li, Jing
5Pan, Jieping
6Wang, Xiangdang
7Ren, Tianli
8Zhang, Yu
9Chen, Zhiwei
10Feng, Xuebing
11Sun, Lingyun
formatjournal
genrearticle
ristypeJOUR
atitleThalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China
jtitleClinical rheumatology
stitleClin Rheumatol
addtitleClin Rheumatol
date2016-04-21
risdate2016
volume35
issue6
spage1521
epage1527
pages1521-1527
issn0770-3198
eissn1434-9949
abstractThalidomide is effective for treating severe cutaneous lupus patients. The aim of this study was to observe the optimum effective and maintenance doses of thalidomide to maximize clinical benefit and minimize side effects for patients with cutaneous lupus in China. Sixty-nine patients with lupus rash from eight hospitals in China were enrolled and treated with different doses of thalidomide. We started the dose of thalidomide at 25 mg daily and gradually increased administration dose once a week until erythema was markedly improved. The effective and maintenance doses were documented. The size of skin lesions was noted once a week. Systemic lupus erythematosus disease activity index (SLEDAI) score, levels of erythrocyte sedimentation rate (ESR), and serum TNF-α were measured before and after treatment. The remission rates were evaluated weekly until 8 weeks. Sixty-eight percent of patients showed an effective dose of 50 mg daily; another 13, 10, and 9 % of patients had an effective dose of 100, 75, and 25 mg daily, respectively. The maintenance dose was 50 mg daily for 71 % of the patients, and 100, 75, and 25 mg daily for 9, 14, and 6 % of the patients. SLEDAI score and serum ESR levels significantly decreased 4 weeks after thalidomide treatment. At the end of the fourth week, the rates of complete remission, partial remission, and no response were 56 % ( n  = 39), 41 % ( n  = 28), and 3 % ( n  = 2). At the eighth week, the rate of total remission rose up to 100 %. The most common side effects were drowsiness and constipation. No peripheral neuropathy was observed in these patients. Thalidomide at a dose of 50 mg daily may offer a better benefit to risk ratio in the treatment of Chinese cutaneous lupus patients.
copLondon
pubSpringer London
pmid27097914
doi10.1007/s10067-016-3256-3